Next Article in Journal
DeepDualEnhancer: A Dual-Feature Input DNABert Based Deep Learning Method for Enhancer Recognition
Previous Article in Journal
Supraspinatus Muscle Regeneration Following Rotator Cuff Tear: A Study of the Biomarkers Pax7, MyoD, and Myogenin
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Guarnera et al. KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives. Int. J. Mol. Sci. 2024, 25, 9023

by
Luca Guarnera
1,2,
Matteo D’Addona
1,
Carlos Bravo-Perez
1,3 and
Valeria Visconte
1,*
1
Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44114, USA
2
Department of Biomedicine and Prevention, Tor Vergata University of Rome, 00133 Rome, Italy
3
Department of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, CIBERER—Instituto de Salud Carlos III, University of Murcia, IMIB-Pascual Parrilla, 30005 Murcia, Spain
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(21), 11743; https://doi.org/10.3390/ijms252111743
Submission received: 25 October 2024 / Accepted: 28 October 2024 / Published: 1 November 2024
(This article belongs to the Section Molecular Biology)
There was an error in the original publication [1]. The oncogenic rearrangements in infant ALL are always somatic, not constitutive or inherited. As correctly indicated in the publication, there is a dramatic incidence of KMT2A rearrangements during infanthood, constituting the driver genetic alteration in 80% of acute leukemias during this period. KMT2A-rearranged ALL normally has a poor prognosis. In this manuscript, the term “germline KMT2A rearrangement” is incorrect and needs clarification. Instead, it was intended to specify that 20% of the infants with ALL which were not KMT2A-rearranged, also known as KMT2A-germline since the gene remained in its unaltered (germline) configuration, were found to carry rearrangements in other oncogenes. Similarly, the term “germline KMT2A::NUTM1” is not correct. Instead, in the KMT2A-germline cases, genetic analysis showed an enrichment in the NUTM1 and PAX5 rearrangements, which were fused to partners not including KMT2A. Genetic correlation studies revealed that NUTM1 rearrangements have a favorable prognosis (PFS of 75–95%), while PAX5 and other gene rearrangements have a high risk of relapse.
A correction has been made to “Chapter 3.1. Incidence, Clinical Features, and Prognosis in Infancy and Childhood”, first paragraph, as follows:
There is a dramatic incidence of KMT2A rearrangements in infants, constituting the driver genetic alteration in 80% of the acute leukemias during this period. Most of them are B-ALL (80–90%), followed by T-ALL, AML (up to 5–10% each), and other disease subtypes (<5%) [21]. Molecularly, the most frequent fusion partners of KMT2A are AFF1, MLLT1, and MLLT3 [1]. Infant-onset B-ALL with KMT2A rearrangement normally exerts a very immature phenotype (pro-B), with the frequent aberrant co-expression of myeloid markers. Patients normally present with hyperleukocytosis and extramedullary disease with central nervous system involvement and have a poor prognosis [22]. The other 20% of infant ALL cases that were not KMT2A-rearranged, also known as KMT2A-germline since the gene remained in its unaltered (germline) configuration, were found to carry somatic rearrangements in other oncogenes. Genetic analysis showed an enrichment in the NUTM1 and PAX5 rearrangements. Clinically, KMT2A-germline cases are normally B-ALLs with a more mature immunophenotype. Genetic correlation studies have revealed that NUTM1 rearrangements have an unusual favorable prognosis as compared to the rest of the infant ALL (PFS of 75–95%), while PAX5 and other gene rearrangements have a high risk of relapse [23–26].
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Guarnera, L.; D’Addona, M.; Bravo-Perez, C.; Visconte, V. KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives. Int. J. Mol. Sci. 2024, 25, 9023. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Guarnera, L.; D’Addona, M.; Bravo-Perez, C.; Visconte, V. Correction: Guarnera et al. KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives. Int. J. Mol. Sci. 2024, 25, 9023. Int. J. Mol. Sci. 2024, 25, 11743. https://doi.org/10.3390/ijms252111743

AMA Style

Guarnera L, D’Addona M, Bravo-Perez C, Visconte V. Correction: Guarnera et al. KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives. Int. J. Mol. Sci. 2024, 25, 9023. International Journal of Molecular Sciences. 2024; 25(21):11743. https://doi.org/10.3390/ijms252111743

Chicago/Turabian Style

Guarnera, Luca, Matteo D’Addona, Carlos Bravo-Perez, and Valeria Visconte. 2024. "Correction: Guarnera et al. KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives. Int. J. Mol. Sci. 2024, 25, 9023" International Journal of Molecular Sciences 25, no. 21: 11743. https://doi.org/10.3390/ijms252111743

APA Style

Guarnera, L., D’Addona, M., Bravo-Perez, C., & Visconte, V. (2024). Correction: Guarnera et al. KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives. Int. J. Mol. Sci. 2024, 25, 9023. International Journal of Molecular Sciences, 25(21), 11743. https://doi.org/10.3390/ijms252111743

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop